Last reviewed · How we verify
opiate with bolus
opiate with bolus is a Small molecule drug developed by Swiss Paraplegic Research, Nottwil. It is currently in Phase 2 development.
Opiates are small molecule substances used to treat various conditions, including pain, postoperative pain, and cancer pain, as indicated by ClinicalTrials.gov. They are administered in bolus form, which is a single, immediate dose, often used in medical settings such as postoperative care.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | opiate with bolus |
|---|---|
| Sponsor | Swiss Paraplegic Research, Nottwil |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- Small Study Comparing Two Pain Medicines in Teenagers for Pain Control After Scoliosis Corrective Surgery. (NA)
- Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute Myocardial Infarction (PHASE3)
- Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surgery (NA)
- Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank (PHASE1)
- Opioid Antagonism in Hypogonadotropic Hypogonadism (PHASE1)
- Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery (PHASE4)
- Effect of Dezocine Versus Nalbuphine Combined With Sufentanil on Postoperative Analgesia, Complications, and Free Flap Survival in Patients Undergoing Oral Cancer Radical Surgery: A Randomized Controlled Clinical Trial. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- opiate with bolus CI brief — competitive landscape report
- opiate with bolus updates RSS · CI watch RSS
- Swiss Paraplegic Research, Nottwil portfolio CI
Frequently asked questions about opiate with bolus
What is opiate with bolus?
Who makes opiate with bolus?
What development phase is opiate with bolus in?
Related
- Manufacturer: Swiss Paraplegic Research, Nottwil — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing